Post

AstraZeneca and Daiichi Sankyo’s ADC improves survival in NSCLC trial

AstraZeneca and Daiichi Sankyo have reported high-level overall survival (OS) results from the Phase III TROPION-Lung01 clinical trial of datopotamab deruxtecan …

HI-Bio reports findings from Phase II trial in kidney transplant recipients

Human Immunology Biosciences (HI-Bio) has reported positive outcomes from the Phase II clinical trial of felzartamab, in treating late antibody-mediated …

Apellis and Sobi report data from Phase II C3 glomerulopathy trial

Apellis Pharmaceuticals and Sobi have announced positive one-year data from the Phase II NOBLE trial of pegcetacoplan in treating post-transplant …

Novartis’ atrasentan shows to reduce proteinuria in Phase III IgAN trial

Novartis has unveiled interim results from the Phase III ALIGN clinical trial where atrasentan showed to reduce proteinuriain Immunoglobulin A …

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

MediLink Therapeutics has announced early data with a HER3 antibody drug conjugate (ADC) that the biotech is codeveloping with BioNTech, …